BetterLife Pharma Inc. (BETRF)
USD 0.07
(0.0%)
USD 0.07
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 8.02 Million CAD | 5.42% |
| 2023 | 7.6 Million CAD | 50.89% |
| 2022 | 5.04 Million CAD | -15.24% |
| 2021 | 5.94 Million CAD | 6.34% |
| 2020 | 5.59 Million CAD | 9.99% |
| 2019 | 5.08 Million CAD | 860.55% |
| 2018 | 529.51 Thousand CAD | -74.86% |
| 2017 | 2.1 Million CAD | 246.26% |
| 2016 | 608.17 Thousand CAD | 755.94% |
| 2015 | 71.05 Thousand CAD | -90.62% |
| 2014 | 757.68 Thousand CAD | 11.31% |
| 2013 | 680.69 Thousand CAD | -33.75% |
| 2012 | 1.02 Million CAD | -65.39% |
| 2011 | 2.96 Million CAD | 19945.26% |
| 2010 | 14.8 Thousand CAD | 0.0% |
| 2009 | - CAD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 7.18 Million CAD | -2.54% |
| 2024 FY | 8.02 Million CAD | 5.42% |
| 2024 Q4 | 8.02 Million CAD | 11.6% |
| 2024 Q1 | 7.12 Million CAD | -6.36% |
| 2024 Q2 | 7.37 Million CAD | 3.51% |
| 2023 Q1 | 6.56 Million CAD | 30.15% |
| 2023 FY | 7.6 Million CAD | 50.89% |
| 2023 Q4 | 7.6 Million USD | 10.28% |
| 2023 Q3 | 6.89 Million CAD | -1.84% |
| 2023 Q2 | 7.02 Million CAD | 7.1% |
| 2022 Q3 | 3.78 Million CAD | -14.14% |
| 2022 FY | 5.04 Million CAD | -15.24% |
| 2022 Q4 | 5.04 Million CAD | 33.15% |
| 2022 Q2 | 4.41 Million CAD | -16.25% |
| 2022 Q1 | 5.26 Million CAD | -11.47% |
| 2021 Q4 | 5.94 Million CAD | -42.92% |
| 2021 Q2 | 4.28 Million CAD | 12.38% |
| 2021 FY | 5.94 Million CAD | 6.34% |
| 2021 Q1 | 3.81 Million CAD | -31.85% |
| 2021 Q3 | 10.42 Million CAD | 143.23% |
| 2020 Q3 | 1.48 Million CAD | 7.83% |
| 2020 FY | 5.59 Million CAD | 9.99% |
| 2020 Q1 | 6.18 Million CAD | 21.52% |
| 2020 Q2 | 1.37 Million CAD | -77.79% |
| 2020 Q4 | 5.59 Million CAD | 277.88% |
| 2019 Q4 | 5.08 Million CAD | 6.18% |
| 2019 Q3 | 4.78 Million CAD | -14.24% |
| 2019 Q2 | 5.58 Million CAD | 3.01% |
| 2019 FY | 5.08 Million CAD | 860.55% |
| 2019 Q1 | 5.42 Million CAD | 924.0% |
| 2018 Q4 | 529.51 Thousand CAD | 17.18% |
| 2018 Q3 | 451.86 Thousand CAD | -72.54% |
| 2018 Q2 | 1.64 Million CAD | -32.97% |
| 2018 Q1 | 2.45 Million CAD | 16.6% |
| 2018 FY | 529.51 Thousand CAD | -74.86% |
| 2017 Q4 | 2.1 Million CAD | 12.9% |
| 2017 Q2 | 943.18 Thousand CAD | 33.26% |
| 2017 FY | 2.1 Million CAD | 246.26% |
| 2017 Q1 | 707.77 Thousand CAD | 16.38% |
| 2017 Q3 | 1.86 Million CAD | 97.77% |
| 2016 Q3 | 143.95 Thousand CAD | 56.82% |
| 2016 FY | 608.17 Thousand CAD | 755.94% |
| 2016 Q2 | 91.8 Thousand CAD | -3.37% |
| 2016 Q1 | 95 Thousand CAD | 33.71% |
| 2016 Q4 | 608.17 Thousand CAD | 322.46% |
| 2015 Q4 | 71.05 Thousand CAD | -90.88% |
| 2015 FY | 71.05 Thousand CAD | -90.62% |
| 2015 Q3 | 778.83 Thousand CAD | 26.7% |
| 2015 Q2 | 614.71 Thousand CAD | 7.19% |
| 2015 Q1 | 573.48 Thousand CAD | -24.31% |
| 2014 Q3 | 784.7 Thousand CAD | 11.99% |
| 2014 Q2 | 700.67 Thousand CAD | 5.16% |
| 2014 Q1 | 666.27 Thousand CAD | -2.12% |
| 2014 FY | 757.68 Thousand CAD | 11.31% |
| 2014 Q4 | 757.68 Thousand CAD | -3.44% |
| 2013 Q4 | 680.69 Thousand CAD | 9.82% |
| 2013 Q1 | 436.8 Thousand CAD | -57.49% |
| 2013 Q2 | 559.28 Thousand CAD | 28.04% |
| 2013 FY | 680.69 Thousand CAD | -33.75% |
| 2013 Q3 | 619.84 Thousand CAD | 10.83% |
| 2012 Q1 | 891.21 Thousand CAD | -69.98% |
| 2012 Q2 | 665.22 Thousand CAD | -25.36% |
| 2012 Q3 | 395.63 Thousand CAD | -40.53% |
| 2012 Q4 | 1.02 Million CAD | 159.69% |
| 2012 FY | 1.02 Million CAD | -65.39% |
| 2011 FY | 2.96 Million CAD | 19945.26% |
| 2011 Q1 | 22.67 Thousand CAD | 53.14% |
| 2011 Q2 | 24.16 Thousand CAD | 6.57% |
| 2011 Q3 | 25 Thousand CAD | 3.45% |
| 2011 Q4 | 2.96 Million CAD | 11773.06% |
| 2010 FY | 14.8 Thousand CAD | 0.0% |
| 2010 Q4 | 14.8 Thousand CAD | 0.0% |
| 2009 FY | - CAD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 84.954% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 16.296% |
| SQZ Biotechnologies Company | 50.03 Million USD | 83.971% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 88.933% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 86.409% |
| Mesoblast Limited | 188.44 Million USD | 95.744% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -108.248% |
| Genus plc | 485 Million USD | 98.346% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -37.276% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -218.739% |
| Marizyme, Inc. | 26.67 Million USD | 69.933% |
| ContraFect Corporation | 32.53 Million USD | 75.345% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -111.066% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -304.809% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -109.542% |
| Intellipharmaceutics International Inc. | 12 Million USD | 33.211% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 31.904% |
| MultiCell Technologies, Inc. | 1617.67 USD | -495706.438% |
| Accustem Sciences Inc. | 1.07 Million USD | -643.164% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 89.64% |
| EV Biologics, Inc. | 2.11 Million USD | -279.208% |
| Q BioMed Inc. | 8.13 Million USD | 1.382% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 90.329% |
| Neon Bloom, Inc. | 1.22 Million USD | -554.088% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -55.858% |
| Biomind Labs Inc. | 1.49 Million USD | -435.196% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 244.07 Million USD | 96.714% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 56.418% |
| Skye Bioscience, Inc. | 14.07 Million USD | 43.005% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -299.005% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -5544.472% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 15.27% |
| IMV Inc. | 37.93 Million USD | 78.856% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -3888.003% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -39.589% |
| GB Sciences, Inc. | 5.41 Million USD | -48.047% |
| Alpha Cognition Inc. | 7.16 Million USD | -11.944% |
| HST Global, Inc. | 593.59 Thousand USD | -1251.18% |
| CSL Limited | 18.62 Billion USD | 99.957% |
| Halberd Corporation | 728.71 Thousand USD | -1000.632% |
| Enzolytics Inc. | 365.26 Million USD | 97.804% |
| Resverlogix Corp. | 67.39 Million USD | 88.099% |
| Affymax, Inc. | 8.87 Million USD | 9.587% |
| SYBLEU INC | 681.41 Thousand USD | -1077.041% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -856.266% |
| argenx SE | 444.95 Million USD | 98.197% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 89.295% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -367.941% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 32.618% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -118.831% |
| AVAX Technologies, Inc. | 3.99 Million USD | -100.827% |
| Zenith Capital Corp. | 27.56 Thousand USD | -28992.502% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.395% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -3260.728% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -114.779% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -1078.042% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 93.244% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 11.299% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -11883.612% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -459.365% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 84.043% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -195.781% |
| BioStem Technologies, Inc. | 15.9 Million USD | 49.571% |
| ONE Bio Corp. | 27.49 Million USD | 70.83% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -1625.959% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -29136.729% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -536.957% |
| Agentix Corp. | 2.51 Million USD | -219.472% |
| LadRx Corporation | 2.2 Million USD | -264.481% |
| Cell Source, Inc. | 15.8 Million USD | 49.259% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -17844.586% |
| Regen BioPharma, Inc. | 5.45 Million USD | -46.96% |
| Regen BioPharma, Inc. | 5.45 Million USD | -46.96% |
| NovAccess Global Inc. | 7.86 Million USD | -2.033% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 67.589% |
| Itoco Inc. | 1.65 Million USD | -385.165% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -290.946% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -32.592% |
| Kadimastem Ltd | 3.5 Million USD | -128.839% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -1802.543% |
| CytoDyn Inc. | 127.89 Million USD | 93.729% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -19088.287% |
| Mobile Lads Corp. | 1.31 Million USD | -510.623% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -412.042% |
| Qrons Inc. | 1.48 Million USD | -438.755% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 27.385% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -891.663% |
| Rebus Holdings, Inc. | 5.24 Million USD | -53.005% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -31.443% |
| International Stem Cell Corporation | 5.27 Million USD | -51.99% |
| Bioxytran, Inc. | 3.24 Million USD | -146.823% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -1181.623% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -73.712% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 80.436% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 63.977% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -295.999% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -46.413% |
| Neutra Corp. | 973.52 Thousand USD | -723.86% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 72.357% |
| PureTech Health plc | 125.58 Million USD | 93.613% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -113.475% |
| IXICO plc | 1.9 Million USD | -322.067% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 60.931% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 92.238% |
| CSL Limited | 18.62 Billion USD | 99.957% |
| Cellectis S.A. | 249.36 Million USD | 96.784% |